期刊
CLINICAL AND TRANSLATIONAL MEDICINE
卷 11, 期 2, 页码 -出版社
JOHN WILEY & SONS LTD
DOI: 10.1002/ctm2.335
关键词
arsenic trioxide; cancer stem cell; differentiation therapy; hepatocellular carcinoma
资金
- National Key Research and Development Program [2019YFC1315800, 2019YFC1315802, 2016YFC0902400, 2016YFF0101405]
- State Key Program of National Natural Science of China [8183000244, 81530077]
- National Natural Science Foundation of China [81602581, 81872355, 81602543, 81672839, 81572823, 81772578, 81802991]
- Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12020105, XDA12020103]
- Shanghai Municipal Key Clinical Specialty and Shanghai Hospital Development Center [SHDC12015104]
Differentiation-inducing therapy using arsenic trioxide (ATO) was shown to effectively induce differentiation of hepatocellular carcinoma (HCC) cancer stem cells (CSCs) by downregulating CSC-related genes and suppressing tumorigenicity. Combinatorial treatment with ATO and 5-fluorouracil/cisplatin enhanced therapeutic effects through synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways in HCC cells. These findings provide new insights for clinical treatment of HCC.
Objective Differentiation-inducing therapy for tumors is a strategy that aims to induce the differentiation and maturation of cancer stem cells (CSCs). The differentiation-inducing capacity of arsenic trioxide (ATO) in hepatocellular carcinoma (HCC) and the underlying mechanism were previously unknown. Methods In the present study, we explored the ATO-induced differentiation of CSCs in HCC by detecting the expression of CSC-related markers and tumorigenicity variation in vivo and in vitro. We developed a combined chemotherapeutic approach to HCC by characterizing the effects of combinatorial treatment with 5-fluorouracil (5-FU)/cisplatin and ATO in vitro and in patient-derived xenograft models. Changes in gene expression patterns were investigated by gene microarray analysis. Results ATO effectively induced differentiation of CSCs by downregulation of CSC-related genes and suppression of tumorigenicity capability. Combinatorial treatment with ATO and 5-FU/cisplatin significantly enhanced therapeutic effects in HCC cells compared with the treatment with 5-FU/cisplatin alone. Synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways by ATO and 5-FU/cisplatin is a potential molecular mechanism underlying the differentiation effect. Conclusions ATO induced the differentiation of HCC CSCs and potentiated the cytotoxic effects of 5-FU/cisplatin through synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways. These results offer new insights for the clinical treatment of HCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据